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ABSTRACT
Overexpression of the ErbB2/HER2 receptor tyrosine kinase occurs in up to 20% 
of human breast cancers and correlates with aggressive disease. Several efficacious 
targeted therapies, including antibodies and kinase inhibitors, have been developed 
but the occurring of resistance to these agents is often observed. New therapeutic 
agents targeting the endocytic recycling and intracellular trafficking of membrane in 
tumor cells overexpressing ErbB2 are actually in clinical development. Nevertheless 
the mechanisms underlying ErbB2 downregulation are still obscure. We have 
previously demonstrated that the overexpression of the p130Cas adaptor protein in 
ErbB2 positive breast cancer, promotes tumor aggressiveness and progression. Here 
we demonstrate that lowering p130Cas expression in breast cancer cells is sufficient to 
induce ErbB2 degradation by autophagy. Conversely, p130Cas overexpression protects 
ErbB2 from degradation by autophagy. Furthermore, this autophagy-dependent 
preferential degradation of ErbB2 in absence of p130Cas is due to an increased ErbB2 
ubiquitination. Indeed, the overexpression of p130Cas impairs ErbB2 ubiquitination by 
inhibiting the binding of Cbl and CHIP E3 ligases to ErbB2. Finally, our results indicate 
that p130Cas-dependent ErbB2 protection from degradation by autophagy may alter 
the sensitivity to the humanized monoclonal antibody trastuzumab. Consistently, in 
human ErbB2 positive breast cancers that develop resistance to trastuzumab, p130Cas 
expression is significantly increased suggesting that elevated levels of p130Cas can 
be involved in trastuzumab resistance.
INTRODUCTION
Molecular and clinical studies indicate that 
ErbB2 has important implications in tumor etiology 
and progression. Overexpression of ErbB2 (Her2/
Neu), is involved in the pathogenesis of nearly 20–30% 
of invasive breast cancers and is associated with an 
aggressive phenotype. Although ErbB2 overexpression 
identifies patients who are likely to respond to therapy 
with trastuzumab, not all patients benefit from treatment. 
Approximately 15% of patients relapse after therapy due 
to de novo or acquired resistance [1–3]. Therefore, intense 
investigations are necessary to understand the factors that 
contribute to the resistance and to identify therapeutic 
strategies to overcome the resistance. Several mechanisms 
have been proposed for the acquirement of resistance 
including the poor internalization of ErbB2 resulting in a 
long half-life at the plasma membrane [4–7]. Although it 
has been shown that Hsp90 inhibition can induce ErbB2 
ubiquitination followed by its downregulation [8, 9], the 
mechanisms underlying ErbB2 downregulation are still 
obscure.
p130Cas is a signaling molecule involved in 
the linkage of actin cytoskeleton to the extracellular 
matrix during cell migration, cell invasion and cell 
transformation. p130Cas protein has been described as 
a major player in the cross-talk between EGF Receptor 
and integrins [10]. Due to its modular structure, p130Cas 
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has been shown to play a crucial role in signaling 
originating from many amplified or mutated oncogenes, 
by undergoing hyperphosphorylation and association with 
multiple signaling partners required for transformation 
[11–13].
The overexpression of p130Cas in the mammary 
gland leads to hyperplasia and delayed involution but 
does not promote tumorigenesis [14]. Double transgenic 
mice originated by crossing MMTV-p130Cas and 
MMTV-NeuT mice, which express the oncogenic form of 
the rat neu gene, homologous to human ErbB2, showed 
an accelerated onset of mammary tumor formation. 
Moreover, the analysis of human breast samples revealed 
that tumors overexpressing both p130Cas and ErbB2 
are characterized by an elevated proliferation index 
[14]. Our previous data demonstrated that p130Cas is an 
essential transducer element in ErbB2 transformation and 
progression showing that p130Cas is necessary for ErbB2-
dependent foci formation, anchorage-independent growth, 
in vivo tumor growth and metastatization [15]. Moreover, 
we have reported that p130Cas over-expression promotes 
ErbB2-dependent invasion in three-dimensional (3D) 
cultures of human mammary epithelial cells and we have 
identified the gene expression changes underlying this 
invasive behavior [16, 17].
Moreover, p130Cas has been proposed as a crucial 
modulator of both anti-estrogen and adriamycin resistance 
[18, 19].
Here we demonstrate that in breast cancer cells 
overexpressing ErbB2, p130Cas protects ErbB2 from 
autophagy-mediated degradation by interfering with 
its ubiquitination. Moreover, changes on the receptor 
ubiquitination caused by modulation of p130Cas 
expression leads to expression of different types of 
autophagic markers, suggesting a link between ErbB2 
degradation and autophagy in a p130Cas-dependent 
manner. Here we show for the first time that high levels 
of p130Cas expression might be crucial to promote 
resistance to trastuzumab treatment by protecting ErbB2 
from degradation.   
RESULTS
Modulation of p130Cas expression interferes with 
ErbB2 protein stability
To investigate the relevance of the modulation of 
p130Cas expression in the control of ErbB2 stability we 
used, as an experimental model, ErbB2 positive BT474 
breast cancer cells. We infected cells with lentiviruses 
expressing either p130Cas shRNAs or scramble control 
shRNA sequences, and lentiviruses overexpressing 
p130Cas with related control vectors. Within 48 hours, 
p130Cas expression was effectively silenced by about 
80% compared to cells infected with scramble sequences, 
while p130Cas overexpression resulted in about 30–40% 
increase of protein expression compared to control infected 
cells (Figure 1A). Interestingly, when we evaluated ErbB2 
expression in these cell lysates, we found that p130Cas 
expression modulation results in changes of ErbB2 
expression levels. Indeed, lowering p130Cas expression 
in BT474 cells (Figure 1A) is sufficient to cause ErbB2 
downregulation. The same results were obtained by 
performing experiments in ErbB2 positive breast cancer 
cell line SKBR3, further supporting the expression 
correlation between ErbB2 and p130Cas (Supplementary 
Figure 1A). To exclude that the ErbB2 downregulation 
is an off-target effect of sh-p130Cas sequence, we tested 
four different sequences and we confirmed that lowering 
p130Cas expression results in ErbB2 downregulation 
(Supplementary Figure 1B). Consistently, overexpression 
of p130Cas leads to an increase of ErbB2 expression 
(Figure 1A). These changes in ErbB2 expression upon 
modulation of p130Cas expression, were not dependent 
on alterations of HER2 gene transcription as shown in 
Figure 1B, (right panel) but rather to its availability on the 
cell membrane as demonstrated by FACS analysis (Figure 
1C). In addition, the alterations of ErbB2 expression upon 
modulation of p130Cas expression were highly specific, 
since no expression changes were observed for Hsp90 and 
ER alpha (Figure 1D).
Therefore, these data indicate that modulation of 
p130Cas expression in breast cancer cells is sufficient to 
strongly affect ErbB2 expression.
p130Cas silencing drives proteasome independent-
ErbB2 degradation
Little attention has been paid to the role of ErbB2 
degradation in cancers, although when compromised, it 
may lead to increased ErbB2 levels and activity. Several 
studies have shown that endocytic downregulation of 
ErbB2 is impaired in cancer cells although there is 
poor understanding of how this is achieved [4, 20]. 
It was recently demonstrated that treatment of ErbB2 
positive SKBR3 and BT474 breast cancer cell lines 
with proteasome inhibitor causes a 50% downregulation 
of ErbB2 protein expression ([21] and Supplementary 
Figure 2), indicating that ErbB2 degradation is proteasome 
independent. In addition, p130Cas has been recently 
described to regulate cell sensitivity to proteasome 
inhibition [22].
To understand whether ErbB2 altered protein levels, 
as a consequence of modulation of p130Cas expression, 
implicate proteasome activity, we treated p130Cas 
silenced, p130Cas overexpressing and relative BT474 
control cells for 16 hours with the proteasome inhibitor 
MG132. As shown in Figure 2, proteasome inhibition 
induces ErbB2 degradation in control cells, as previously 
demonstrated. However, we observed a significant 
increased degradation of ErbB2 in p130Cas silenced cells 
compared to control cells following treatment with 2 µM 
of MG132 for 16 hours, while overexpression of p130Cas 
minimizes the degradation of ErbB2 upon proteasome 
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inhibition. Interestingly, these data indicate that lowering 
p130Cas expression can lead to further degradation of 
ErbB2, while the overexpression of p130Cas protects 
ErbB2 from degradation. Moreover, treatment of 
p130Cas silenced and relative BT474 control cells with 
cycloheximide with or without MG132, indicates that 
ErbB2 degradation is prompted in p130Cas-silenced 
conditions (Supplementary Figure 3). 
It was previously demonstrated that ErbB2 
degradation upon proteasome inhibition leads to the 
formation of cytosolic aggregates directed to lysosomal 
degradation [23]. Consistently, the treatment of control 
(Ctr) cells with MG132 induced a reduction of ErbB2 
level and an increased amount of the autophagic markers 
LC3-II (Figure 2 left and right panels), indicating that 
the induction of autophagy correlates with decreased 
ErbB2 protein levels. Noteworthily, the downregulation 
of p130Cas is sufficient to lower ErbB2 expression 
and to enhance the conversion of LC3-I to its lipidated 
form LC3-II respect to the control and to the p130Cas 
overexpressing cells, suggesting that p130Cas-dependent 
ErbB2 degradation is due to an increased activation of 
the autophagic process. These experiments were also 
performed in SKBR3 cell lines showing the same results 
(Supplementary Figure 4A and 4B). 
Most interestingly, high levels of p130Cas expression 
that protect ErbB2 from degradation correlate with low 
expression of the autophagy marker LC3-II independently 
of proteasome inhibition. These data indicate that in 
ErbB2 positive cells silenced for p130Cas and treated 
Figure 1: Modulation of p130Cas expression specifically affects ErbB2 expression. (A) Left panel: Total cell lysates of 
BT474 cells infected with lentiviral vectors to silence (Cas sh) or overexpress p130Cas (Cas over) were blotted with p130Cas and ErbB2 
antibodies. GAPDH was used as loading control. Right panel: Histograms show ErbB2 and p130Cas levels, normalized to GAPDH. Bars 
represent the means ± SEM of three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001). (B) qRT-PCR analysis of p130Cas 
mRNA (left panel) and ErbB2 mRNAs (right panel) expression from cells as in (A). Quantification of results from three independent 
experiments is shown (ns: not significant; **p < 0.01: ***p < 0.001). (C) Histograms show the expression of cell membrane ErbB2 
evaluated by FACS analysis on control, p130Cas silenced and p130Cas overexpressing BT474 cells. Bars represent the means ± SEM of 
three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001). (D) Total cell lysates obtained from cells as in (A) were probed with 
antibodies to ErbB2, p130Cas, Hsp90 and ER alpha and normalized with GAPDH.
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with MG132, p130Cas inhibition leads to a stronger 
activation of the autophagic flux leading to increased 
ErbB2 degradation whereas p130Cas overexpression is 
sufficient to impair autophagy thereby preventing ErbB2 
degradation.
p130Cas expression level alters sensitivity of 
breast cancer cells to autophagy
To demonstrate that the p130Cas expression can 
interfere with the autophagic degradation of ErbB2, Ctr, 
p130Cas silenced and overexpressing BT474 cells were 
starved and cultured for 6 hours in presence of HBSS 
(Hank’s balanced salt solution) to induce autophagy alone 
or in combination with Chloroquine, a drug that arrests 
the latter step of autophagy, resulting in the failure of 
the autophagy process [24]. Cell lysates from control, 
p130Cas silenced and overexpressing cells were collected 
and western blot analysis performed. The results shown in 
Figure 3A (left and right panels) confirm that in untreated 
cells, silencing of p130Cas is sufficient to induce ErbB2 
downregulation by autophagy as demonstrated by LC3-
II upregulation. In addition, the induction of autophagy 
by HBSS treatment leads to approximately 50% 
reduction of ErbB2 in Ctr cells compared to untreated 
cells demonstrating that autophagy is implicated in 
the degradation of ErbB2. The effectiveness of HBSS 
treatment to trigger the autophagic flux is confirmed by the 
presence of the lipidated form of LC3. Most interestingly, 
in p130Cas overexpressing cells the HBSS treatment does 
not significantly affect ErbB2 expression levels indicating 
that the overexpression of p130Cas renders ErbB2 
less sensitive to autophagy degradation. Moreover, the 
concomitant treatment of HBSS and Chloroquine results 
in the re-establishment of ErbB2 expression in p130Cas 
silenced cells upon autophagy inhibition (Figure 3A) 
and the concomitant accumulation of LC3-II expression, 
confirming that absence of p130Cas favors ErbB2 
degradation through autophagy.
Accordingly, as shown in Figure 3B (left and right 
panels), the treatment with Chloroquine (100 µM) was 
sufficient to restore ErbB2 levels in both control and 
p130Cas silenced cells, while in p130Cas overexpressing 
cells did not result in a significant change in the amount 
of ErbB2 expression. Therefore, these results indicate 
that blocking the autophagic flux, as demonstrated by the 
increased expression of the lipidated form of LC3, rescues 
ErbB2 expression in both control and p130Cas silenced 
cells.
p130Cas-dependent ErbB2 degradation by 
autophagy is regulated by mTOR activity 
It is known that class I and class III of 
phosphatidylinositol 3-kinase (PI3K) can regulate autophagy 
in different ways. In cancer cells the growth factor receptor-
induced activation of class I PI3K/AKT/mTOR axis, inhibits 
autophagy. Conversely, class III PI3K activity is required for 
the sequestration of cytoplasmic material that characterizes the 
autophagic process [25, 26]. 
Figure 2: p130Cas expression prevents proteosome-independent ErbB2 degradation. Left panel: BT474 silenced for or 
overexpressing p130Cas and relative controls were treated for 16 hours with MG132 (2 µM). Protein extracts were then blotted with 
antibodies against ErbB2, p130Cas and LC3. GAPDH was used as loading control. Right panel: Histograms show ErbB2 and LC3-II levels, 
normalized to GAPDH. Bars represent the means ± SEM of five independent experiments (ns: not significant; **p < 0.01; ***p < 0.001).
Oncotarget5www.impactjournals.com/oncotarget
In addition, we have previously demonstrated that 
p130Cas overexpression in ErbB2 transformed cells leads 
to the activation of mTOR [17]. Therefore, to identify 
which autophagy signaling pathways were specifically 
involved in p130Cas-mediated ErbB2 degradation, we 
treated control, p130Cas silenced and overexpressing 
BT474 cells for 16 hours with the mTOR activator 
MHY1485 (2 µM) to block autophagy [27] and with 
mTOR inhibitor rapamycin (100 nM) to induce autophagy.
The results in Figure 4 indicate that treatment with 
Rapamycin in p130Cas silenced cells increased ErbB2 
degradation. As expected, LC3-II expression was present 
following p130Cas silencing in control cells and was 
strongly upregulated in cells treated with Rapamycin. 
Conversely, experiments performed by treating cells with 
the mTOR activator, indicate that the resulting inhibition 
of autophagy is sufficient to reverse ErbB2 levels in 
p130Cas silenced BT474 cells, further confirming the 
key role of p130Cas in affecting signaling leading to 
autophagy that is instrumental for ErbB2 degradation. 
Importantly, p130Cas overexpressing cells were less 
prone to undergo autophagic degradation induced by 
Rapamycin. The inhibition of autophagy in cells treated 
with the mTOR activator is supported by low levels of 
LC3 expression and increased p62/sequestosome-1 protein 
expression. The same results were obtained by using the 
inhibitor of class III PI3K wortmannin, known to inhibit 
autophagy (data not shown) [25]. These data show that 
ErbB2 degradation by autophagy depends on p130Cas 
expression levels, with low levels of p130Cas sensitizing 
Figure 3: p130Cas protects ErbB2 from autophagy-dependent degradation. (A) Left panel: Extracts from p130Cas silenced, 
overexpressing and control (Ctr) BT474 cells cultured for 6 hours in HBSS in absence or presence of chloroquine (100 µM) were blotted 
with antibodies to ErbB2, p130Cas, LC3 and GAPDH as loading control. Right panel: Histograms show ErbB2 levels, normalized to 
GAPDH. Bars represent the means ± SEM of five independent experiments (ns: not significant; **p < 0.01; ***p < 0.001). (B) Left panel: 
BT474 cells as in (A) were treated with 100 µM chloroquine for 6 hours. Cell lysates were blotted with antibodies against ErbB2, p130Cas, 
LC3 and Actin as loading control. Right panel: Histograms show ErbB2 levels, normalized to Actin. Bars represent the means ± SEM of 
four independent experiments (ns: not significant; ***p < 0.001).
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ErbB2 to authophagy degradation and high p130Cas levels 
protecting it from degradation. 
p130Cas protection of ErbB2 from ubiquitination
It has been recently demonstrated that ubiquitin 
can be a crucial element to target protein aggregates to 
selective autophagy [28]. Therefore, we speculated that 
p130Cas can modify ErbB2 sensitivity to autophagy 
degradation by affecting its ubiquitination status. 
Therefore, ErbB2 was immunoprecipitated from 
p130Cas silenced or overexpressing BT474 cells and 
the immunoprecipitates were probed with anti-ubiquitin 
antibodies. As shown in Figure 5A, greater amounts 
of ubiquitinated ErbB2 were observed upon p130Cas 
silencing compared to control cells. In addition, 
higher levels of p130Cas were associated with lower 
ubiquitination of ErbB2. Western blotting analysis on the 
same cell extracts were performed to verify changes in 
ErbB2 level after modulation of p130Cas (Figure 5B). 
These results indicate that the presence or absence 
of p130Cas can affect the ubiquitination of ErbB2. Since 
CHIP and Cbl E3 ligases have been reported to associate 
with ErbB2 and to mediate its ubiquitination [29–31] 
and we have previously demonstrated that p130Cas 
immunoprecipitates with ErbB2 ([15] and Supplementary 
Figure 5), we tested whether the observed differences of 
ErbB2 ubiquitination in presence or absence of p130Cas 
can be due to an impaired accessibility of ErbB2 by 
its E3 ligases. To this end, ErbB2 immunoprecipitates 
from BT474 cells in which p130Cas was silenced or 
overexpressed were probed with Cbl and CHIP antibodies. 
The results show that both CHIP and Cbl association to 
ErbB2 is highly increased in p130Cas silenced cells 
(Figure 5C), indicating that the binding of p130Cas to 
ErbB2 is sufficient to interfere with its polyubiquitination 
by reducing the binding of E3 enzymes, pointing out an 
uncovered chaperone function for p130Cas.
p130Cas sustains ErbB2 stability and resistance 
to trastuzumab
Since activation of ErbB2 downstream signaling and 
increased ErbB2 stability are hallmarks of resistance to 
trastuzumab treatment [32], we hypothesized that p130Cas 
can be a mediator of trastuzumab resistance. To examine 
whether p130Cas levels of expression is involved in 
trastuzumab resistance, experiments were performed in 
ErbB2 overexpressing BT474 and SKBR3 made resistant 
to trastuzumab [33]. Sensitive and resistant cells were first 
compared for levels of p130Cas mRNA and protein levels 
by performing quantitative real-time PCR and western 
blot analysis. The results indicate that transcription 
of p130Cas mRNA and its expression is upregulated 
Figure 4: Inhibition of autophagy is sufficient to rescue p130Cas-dependent ErbB2 expression. Left panel: BT474 
silenced for p130Cas, overexpressing p130Cas and control cells were treated for 16 hours with mTOR activator MHY1485 (2 µM), with 
mTOR inhibitor Rapamycin (100 mM) and DMSO as control. Protein extracts were then blotted with antibodies against ErbB2, p130Cas, 
phospho-S6, S6, p62, LC3 and GAPDH as loading control. Right panel: Histograms show ErbB2, p62 and LC3 II levels, normalized to 
GAPDH. Bars represent the means ± SEM of five independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001).
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in resistant SKBR3R and BT474R cells compared to 
wt cells suggesting a functional role of p130Cas in the 
acquired resistance to trastuzumab (Figure 6A and 6B). 
To assess whether the increased stability of ErbB2 
following p130Cas-dependent inhibition of autophagy is 
a possible mechanism to induce resistance to trastuzumab, 
p130Cas overexpressing BT474 cells and relative controls 
were treated for 24 hours with rapamicyn (100 nM) and 
trastuzumab (10 µM) alone and/or in combination. 
As shown in Figure 6C, the treatment of cells with 
rapamycin and trastuzumab does not affect significantly 
the expression of ErbB2, whereas the combination of 
treatments results in downregulation of ErbB2, confirming 
what previously observed in preclinical studies using 
mTOR inhibitor and trastuzumab alone or in combination 
[34, 35]. Notably, the overexpression of p130Cas, as 
expected, is sufficient to induce the expression of ErbB2 
and to prevent its downregulation in the combined 
treatment observed in control cells. These results indicate 
that the overexpression of p130Cas can be one important 
factor that contributes to trastuzumab resistance.
To further assess the involvement of p130Cas 
in clinical resistance to trastuzumab, we evaluated the 
correlation between p130Cas expression and failure 
to trastuzumab-based therapy in ErbB2 positive breast 
cancer patients. Therefore, we assessed the expression of 
p130Cas in ErbB2 positive primary tumors of 11 patients 
and in the relapsing trastuzumab resistant counterparts. As 
shown in Table 1, 8 out of 11 tumors showed an increase in 
p130Cas expression at the time of progression. Moreover, 
3 out of 11 tumors were already 2+/3+ for p130Cas at 
first diagnosis of breast cancer and they retained this high 
p130Cas positivity after trastuzumab treatment (Figure 
6D). These data suggest that high levels of p130Cas may 
promote acquired resistance to trastuzumab therapy in 
ErbB2 positive breast cancer.  
Overall our results indicate that the modulation 
of p130Cas expression correlates with alterations of 
ErbB2 expression, and in particular we demonstrated that 
p130Cas protects ErbB2 from autophagy degradation. 
This protection from degradation points out p130Cas as 
a crucial player in ErbB2 resistance to targeted therapy. 
DISCUSSION
Here we demonstrate for the first time that the adaptor 
protein p130Cas can act as a protecting agent against 
ErbB2 degradation. Consistently, we show that lowering 
p130Cas expression is sufficient to get ErbB2 degraded 
while p130Cas overexpression increased ErbB2 stability 
at the cell membrane. Our data also show that p130Cas-
dependent ErbB2 degradation occurs preferentially by 
autophagy rather than by proteasome. Interestingly, we have 
demonstrated that the presence of p130Cas can impair the 
binding of the ErbB2 with its E3 ligases CHIP and Cbl, 
resulting in a defective ubiquitination.
Figure 5: p130Cas expression influences ErbB2 ubiquitination. (A) Left panel: Cell extracts from control (Ctr), p130Cas silenced 
and p130Cas overexpressing BT474 cells were immunoprecipitated with ErbB2 antibodies, followed by immunoblotting against Ubiquitin 
and ErbB2 antibodies. Right panel: Histograms show the levels of ubiquitin, normalized to ErbB2. Bars represent the means ± SEM of 
three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001). (B) Cell extracts as in A were probed with antibodies to p130Cas, 
ErbB2 and normalized with Vinculin. (C) Cell extracts from control (Ctr), p130Cas silenced and p130Cas overexpressing BT474 cells were 
immunoprecipitated with ErbB2 antibodies and blotted with Cbl, CHIP and ErbB2 antibodies. 
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We have previously extensively shown that 
p130Cas supports and amplifies ErbB2 downstream 
signaling pathways both in vivo and in vitro promoting 
tumorigenesis and progression [14–17]. Here we describe 
for the first time one possible mechanism through which 
p130Cas can affect ErbB2 tumorigenesis. Our present data 
indicate that p130Cas by binding to ErbB2, stabilizes the 
receptor preventing its ubiquitinylation and subsequent 
degradation by selective autophagy. Indeed p130Cas by 
binding to ErbB2 does not allow the association with 
CHIP and Cbl E3 ligases, possibly due to steric hindrance. 
Conversely, low levels of p130Cas allows the binding 
of CHIP and Cbl E3 ligases to ErbB2 promoting its 
degradation by autophagy. 
It was previously inferred that ErbB2 receptor is 
resistant to down-regulation by endocytosis, probably 
because of its association to Hsp90 chaperone that 
might prevent due to steric hindrance the binding of E3 
ligase to ErbB2 resulting in impaired ubiquitinylation 
and degradation [23]. Indeed Hsp90 inhibitors, such 
as geldamycin, induces a rapid ubiquitin-dependent 
degradation of the receptor [8, 9, 20, 36]. We can speculate 
that p130Cas mirrors in ErbB2 positive breast cancer the 
function of Hsp90, protecting ErbB2 from degradation 
but at the same time, assembling a signaling platform that 
sustains and reinforces breast cancer growth, migration 
and invasion. 
Our data also points out that lowering p130Cas is 
sufficient to induce ErbB2 degradation that preferentially 
occurs by autophagy rather than by proteasome. 
Interestingly, it has been speculated that the 
docking of proteins to be degraded to the ubiquitin-
proteasome system (UPS) or to the autophagy—lysosomal 
pathway depends on the differential attachment of 
ubiquitin moieties. The association with K48-linked 
polyUb chains will represent the recognition signal for 
proteasome degradation, whereas the K63-linked chains 
may preferentially target substrates to degradation by 
autophagy [23, 28, 37, 38]. 
In parallel, it has been recently proposed in SKBR3 
breast cancer cells that ErbB2 degradation is proteasome 
independent and that the conjugation of K63-linked 
Figure 6: p130Cas overexpression promotes resistance to trastuzumab. (A) Quantification of p130Cas mRNA by qRT PCR in 
wild type SKBR3 (SKBr3), in trastuzumab resistant SKBR3 (SKBr3R), in BT474 wild type (BT474) and in trastuzumab resistant BT474 
cells (BT474R). The 18S housekeeping gene was used as an internal control for data normalization. (B) Cell extracts from trastuzumab 
sensitive and resistant SKBR3 and BT474 cells were probed with p130Cas antibodies and normalized with Actin. (C) Cell extracts from 
p130Cas overexpressing BT474 cells and relative control cells untreated or treated with 100 nM Rapamycin (R), 10 µM/ml trastuzumab (T) 
alone or in combination (R + T) were blotted with antibodies against ErbB2, p130Cas, phospho-S6, LC3 and GAPDH as loading control. 
(D) Representative images of p130Cas expression in primary tumor at the time of diagnosis (left panel) and in relapsing trastuzumab 
resistant tumor (right panel) of patient n°2 (see Table 1). 
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polyubquitin chains to ErbB2 might be relevant to target 
its degradation by the autophagy-lysosomal system [21, 
23]. On the basis of these data we can speculate that in the 
absence of p130Cas the observed ErbB2 degradation by 
autophagy might be dependent by an increased amount of 
K63 linkages that in turn are recognized by the autophagy 
receptors and finally degraded. Further investigations 
are needed to verify this hypothesis and to identify the 
molecular players involved in p130Cas-dependent ErbB2 
degradation and/or stability. 
Nevertheless, the translational importance of the 
levels of p130Cas expression in the regulation of ErbB2 
stability is evident. Indeed, the p130Cas silencing in a 
therapeutic setting will contribute to ErbB2 degradation 
and thereby to limitations of its oncogenic properties, 
whereas the overexpression of p130Cas by protecting 
ErbB2 from autophagy can be implicated in resistance 
to trastuzumab treatment. Our data indeed indicate that 
high levels of p130Cas expression inversely correlate 
with ErbB2 sensitivity to trastuzumab and the induction 
of autophagy is not sufficient to promote its degradation. 
The mechanism through which p130Cas mediates 
resistance to trastuzumab might rely on the increased 
ErbB2 stability to the cell membrane. However, it has 
been reported that increased autophagosome formation 
in trastuzumab resistant cells preserves breast cancer cell 
survival [39]. These opposite data can be reconciled by the 
fact that overexpression of p130Cas drives resistance to 
trastuzumab by increasing ErbB2 stability and by blocking 
the receptor ubiquitination and thus its degradation, 
regardless of activation of downstream autophagy flux. 
Our and others previous and current results indicate 
that high levels of p130Cas are hallmarks of breast cancer 
progression, invasion, metastatization and resistance 
[11, 13, 40]. However, the mechanisms through which 
p130Cas expression is upregulated in breast cancer still 
remain an open question. 
In conclusion, we provided evidence that p130Cas 
overexpression prevents ErbB2 degradation by autophagy. 
The resulting increased stabilization of ErbB2 by 
p130Cas might be the crucial event driving breast cancer 
progression and resistance, strengthening the relevance 
of p130Cas as an unfavorable prognostic marker and 
a putative therapeutic target to overcome resistance to 
trastuzumab based treatment in ErbB2 positive breast 
cancers.
MATERIALS AND METHODS
Antibodies 
p130Cas mAbs have been previously described 
[41]. ErbB2 NCL-L-Cb11 mAbs were purchased from 
Novocastra (Leica Microsystems Srl, Germany). An 
additional mAb directed to the cytoplasmic domain of 
ErbB2 were prepared in our laboratory, by immunizing 
mice with a recombinant protein encompassing amino acids 
1031–1160 of rat ErbB2 cDNA sequence. mAbs to Vinculin 
were from Millipore (Billerica, MA, USA). Antibodies to 
c-Src, p-Tyr PY99, Actin, Cbl and CHIP were from Santa 
Cruz Biotechnologies (Palo Alto, CA, USA). pTyr416 c-Src 
and Beclin-1 antibodies were from Cell Signaling (Beverly, 
MA,USA). Mono- and polyubiquitinylated conjugates 
antibody was from Enzo Life Sciences (Farmingdale, NY). 
LC3 polyclonal antibody was from Thermo Scientific Pierce 
Antibodies (Rockford, Illinois). Secondary antibodies 
conjugated with peroxidase were from Sigma-Aldrich 
(St. Louis, MO, USA). 
Table 1: Grade of p130Cas expression in primary and relapsing breast cancer patients before and 
after trastuzumab treatment
Case N° Stage Histology Mol. Subtype Surgery at diagnosis 
p130Cas (IHC 
 before trastuzumab
p130Cas (IHC) 
after trastuzumab
1 III CDI HER2-Enriched Yes 2+ 3+
2 III CDI HER2-Enriched Yes 1+ 3+
3 III CLI HER2-Enriched Yes 1+ 3+
4 III CDI HER2-Enriched Yes 3+ 3+
5 III CDI HER2-Enriched Yes 2+ 3+
6 III CDI Luminal-HER2 Yes 1+ 3+
7 III CDI Luminal-HER2 Yes 2+ 3+
8 IV CDI Luminal-HER2 Not 3+ 3+
9 I CLI HER2-Enriched Yes 1+ 2+
10 III CDI HER2-Enriched Yes 2+ 3+
11 III CDI HER2-Enriched Yes 2+ 2+
CDI: Ductal Infiltrating Carcinoma; CLI: Lobular Infiltrating Carcinoma; IHC: immunohistochemistry. 
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Cell lines
SKBR3 cells were cultured in McCoy’s 5A–15% 
FBS and BT474 cell lines were cultured in DMEM-F12 
with 10% FBS. SKBR3 and BT474 resistant cells were 
respectively cultured in RPMI-1640 10% FBS and 
DMEM 10% FBS. SKBR3 and BT474 made resistant to 
trastuzumab were generated by Dr. Valabrega as described 
in [33]. 
Proteasome and autophagy experiments
For proteasome inhibition experiments, MG132 
(CAS-133407-82-6, Calbiochem, Darmstadt, Germany) 
was directly added into medium at a concentration of 
0.5, 2 and 6 µM for 16 hours. Cycloheximide was used 
at 100 mg/ml and purchased from Sigma (Sigma-Aldrich, 
St. Louis, MO, USA). For autophagy induction cells 
were cultured in Hank’s balanced salt solution (HBSS, 
Invitrogen Life Technologies, Carlsbad, CA, USA) 
for 2, 4 and 6 hours. For autophagy pharmacological 
inhibition, cells were treated with the PI3-kinase inhibitor, 
wortmannin (Enzo Life Sciences, Farmingdale, NY) at 
100 nM and with chloroquine (Sigma-Aldrich, St. Louis, 
MO, USA), an inhibitor of autophagosome formation at 
100 µM for 16 hours. For mTOR inhibition cells were 
treated with rapamycin (Cell Signaling Technology, 
Beverly, MA) at 100 nM for 16 hours. For resistance 
experiments, cells were treated for 20 hours with 
trastuzumab (10 microg/ml) or Rapamycin (100 nM) or 
with combination of both. 
Lentivirus generation
A pLKO.1 lentiviral vector carrying a shRNA 
directed to human p130Cas (p130Cas shRNA) was 
selected in the pLKO.1 target gene shRNA set (clone ID 
TRCN0000115985), purchased from Open Biosystem 
(Huntsville, AL, USA, http://www.thermoscientificbio.
com). pLKO.1 scramble shRNA vector (Addgene, 
Cambridge, MA, USA, http://www.addgene.com) 
was used as negative control. Lentiviral particles were 
generated and concentrated by ultracentrifugation (50,000 g, 
2 hours). BT474 and SKBR3 cells were infected with the 
lentiviral p130Cas-shRNA (sh-p130Cas) and scramble-
shRNA (Ctr). Puromycin (Sigma) (0.5 mg/ml) was added 
24 hours after infection with PLKO.1 vectors as described 
in [42]. For p130Cas expression, human p130Cas cDNA, 
mouse p130Cas cDNA were cloned into pCCL lentiviral 
vector, and viral particles production was performed as 
described in [42].
Immunobloting and immunoprecipitation analysis
Cells were extracted with RIPA buffer (1% Triton 
X-100, 0,1% SDS, 1% sodium deoxycholate, 150 mM 
NaCl, 50 mM Tris-HCl ph 7, 0.4 mM Na3VO4, inhibitor 
mix). Cell lysates were centrifuged at 13,000 g for 
10 minutes and the supernatants were collected and 
assayed for protein concentration with the Bio-Rad protein 
assay method (Biorad, Hercules, CA, USA). Proteins were 
run on SDS-PAGE under reducing conditions. Following 
SDS-PAGE, proteins were transferred to nitrocellulose, 
incubated with specific antibodies and then detected 
with peroxidase conjugated secondary antibodies and 
chemoluminescent ECL reagent. When appropriate, 
the nitrocellulose membranes were stripped according 
to manufacturers’ recommendations and re-probed. 
Densitometric analysis was performed using the GS 250 
Molecular Imager (Biorad). 
For immunoprecipitation assay, 1 mg of cell extracts 
were immunoprecipitated with ErbB2 antibody and then 
probed for specific antibodies. 
For ubiquitination experiments, 10 mg of cell extracts 
were immunoprecipitated with ErbB2 antibody. After 
blotting, the membrane were pre-incubated with denaturing 
buffer (6 M guanidine-HCl, 20 mM Tris-HCl ph 7.5, 5 
mM b-mercapto-ethanol, 1 mM PMSF) for 30′ at 4°C and 
washed in PBS buffer. Then the membrane was blocked with 
5% BSA in TBS buffer for 6 hours at room temperature and 
incubated overnight at 4°C with the anti-ubiquitin antibody.
RNA isolation and qRT-PCR for mRNA detection
Total RNA was isolated from cells using TRIzol™ 
Reagent (Invitrogen Life Technologies, Carlsbad, CA, 
USA). 1 μg of DNAse-treated RNA (RQ1 RNase-
Free DNase kit, Promega, Madison, WI, USA) was 
retrotranscribed with High Capacity cDNA Reverse 
Transcription Kit (Invitrogen Life Technologies, Carlsbad, 
CA, USA). Quantitative PCR was performed on an 
Applied Biosystems, 7900HT Fast Real-Time PCR System 
(standard settings) using the Universal Probe Library 
system (Roche Italia, Monza, Italy) and Platinum™ 
Quantitative PCR SuperMix-UDG (Invitrogen Life 
Technologies, Carlsbad, CA, USA). Results were analyzed 
with the 2−ΔΔCt method using the 18 S rRNA predeveloped 
TaqMan assay (Invitrogen Life Technologies, Carlsbad, 
CA, USA) as an internal control. The median expression 
across samples was used as calibrator. 
In vitro cell assays
For proliferation assay, MTT (4,5 dimethyl-2-yl 
2,5-diphenyl tetrazolium bromide) from Sigma Chemical 
Co. (St. Louis, MO, USA) was performed on SKBR3 and 
BT474 upon treatment with freshly added trastuzumab 
(Herceptin) (2 µg/ml) for 4 days. For FACS analysis 
cells were stained with ErbB2 mAb and with Alexa 
488 secondary antibody (Invitrogen Life Technologies, 
Carlsbad, CA, USA). Alexa 488 emission was detected 
in the green channel (525 nm) following excitation by a 
488 nm laser on a FACS Calibur cytometer (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA).
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Immunohistochemistry procedures
Human investigations were performed with 
informed consent and were preceded by local institutional 
review board approval. 
Samples were routinely fixed in 10% formaldehyde 
buffer (pH 7.4) for 24 hrs, paraffin-embedded, and 
processed for immunohistochemical analysis. Slides 
were incubated with anti-p130Cas (Labvision Thermo 
Scientific) (1 microg/mL) for 1 hr at room temperature, 
after antigen retrieval (citrate buffer, at 98°C for 
40 min). Staining was detected with EnVision System-
HRP Labelled Polymer anti-mouse (DakoCytomation) and 
developed with the LiquidDAB Substrate Pack (BioGenex, 
San Ramon, CA, USA). Nuclei were counterstained with 
Mayer hemallum. Images were taken using a Leica DM 
2000 microscope.
Statistical analysis
The results are representative of at least three 
independent experiments performed in triplicate and are 
expressed as the means ± s.e.m. Statistical analysis of the 
data was performed using a Student’s t-test.
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